Xcout Intel
Agenus Inc.
Agenus Inc. is a biotechnology company headquartered in Lexington, Massachusetts, focused on the discovery and development of better immunotherapies and cancer treatments.
Subscribe to see Agenus Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Agenus Inc. at a glance
Agenus Inc. is a biotechnology company headquartered in Lexington, United States. It is publicly listed (AGEN) with a market capitalisation of $249M. Xcout tracks 22 named people at Agenus Inc., including Jennifer S. Buell (Director and President & Chief Executive Officer of MiNK Therapeutics).
Agenus Inc. leadership
- Jennifer S. BuellDirector and President & Chief Executive Officer of MiNK Therapeutics
- Steven J. O'DayChief Medical Officer
- Craig WinterChief Information Officer
- Robin G. TaylorChief Commercial Officer
- Robin Taylor, Ph.D.Chief Commercial Officer
- Stefanie Perna-NacarChief Communications & Government Relations Officer
16 more named people on record for Agenus Inc., with roles, board committees and tenure — see the full roster →
Agenus Inc. competitors
A few of Agenus Inc.'s closest competitors — see the full list of competitors and alternatives →
Curis, Inc. is a biotechnology company headquartered in Lexington, Massachusetts. The company is engaged in the research and development of drug candidates for the treatment of human cancers.
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
CureLab Oncology Inc. is a clinical-stage biotechnology company headquartered in the greater Boston area that develops new anti-cancer biologics, with its lead product being the immuno-oncology agent Elenagen.
Accent Therapeutics, Inc. is a biopharmaceutical company headquartered in Lexington, Massachusetts, focused on translating scientific research into novel therapeutics. The company conducts clinical trials, such as Phase 1/2 studies, targeting oncology and other serious diseases.
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
Triana Biomedicines, Inc. is a private biotechnology company focused on targeted molecular glue discovery. The company is headquartered in Lexington, Massachusetts.
Get Agenus Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Agenus Inc. in Xcout Intel
- 22 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access